

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number
WO 2004/004691 A1

- (51) International Patent Classification⁷: **A61K 9/127**, 31/155, 31/167, 31/40
- (21) International Application Number:
PCT/EP2003/006745
- (22) International Filing Date: 26 June 2003 (26.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
MI2002A001455 2 July 2002 (02.07.2002) IT
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*
- (71) Applicants and
(72) Inventors: **ARCAMONE, Federico** [IT/IT]; Via IV Novembre, 26, I-20014 Nerviano (MI) (IT). **CITERNESI, Ugo, Raffaello** [IT/IT]; Via del Ronco, 17, I-20043 Arcore (MI) (IT).
- (74) Agents: **MINOJA, Fabrizio** et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).

(54) Title: PHOSPHOLIPID COMPLEXES OF LEXITROPSINS, THEIR PREPARATION AND USE IN THERAPEUTIC FORMULATIONS

(57) Abstract: Pharmaceutical formulations constituted by a lexitropsin phospholipidic complex in the form of liposomes, micelles or nanoparticles exhibit optimal pharmacological properties in respect to other formulations containing active principles belonging to the same chemical class in both the topical or parenteral treatment of infectious and/or tumour diseases.


WO 2004/004691 A1

PHOSPHOLIPID COMPLEXES OF LEXITROPSINS, THEIR PREPARATION AND USE IN THERAPEUTIC FORMULATIONS

SUMMARY OF THE INVENTION

The present invention refers to pharmaceutical formulations constituted by a phospholipidic phase containing a lexitropsin and to their use for the treatment of local or general infections as well as tumour diseases in humans and in animals. Such formulations exhibit optimal pharmacological properties in respect to other, both topical and parenteral, formulations of antiinfective and antitumour agents within the class of the lexitropsins.

Object of the present invention are therefore the preparation and the therapeutic use of formulations based on liposomes, micellar aggregates or more generally phospholipidic complexes containing a lexitropsin of general structure I



I (n=0,1)

in which R₁ is a functional group, preferably a basic one such as a simple or substituted amidine, a secondary or tertiary amine, a quaternary ammonium group, a simple or substituted guanidine, examples of which, without limiting the present invention, may be

-C(NH)NH₂, -C(NH)NHR₃, -NH₂, NHR₃, -N(R₃)₂, -NR₃R₄,
-NH-C(NH)NH₂, -NH-C(NH)NHR₃, -N(CH₂)₄, -N(R₃)₃⁺

whereas R₂ represents an aliphatic, aromatic, or arylaliphatic acyclic group, also if substituted with atomic groups containing one or more

CONFIRMATION COPY

heteroatoms such as atoms of oxygen, nitrogen, or R_2 represents a sequence of one or more residues of 1-methyl-4-aminopyrrole-2-carboxylic acid, acylated or not acylated at the N-terminus, also terminating with a residue of 1-methyl-4-carboxamidopyrrole-2-carboxylic acid or with a residue of analogue amino acids derived from an heterocycle different from pyrrole such as, without limiting the present invention, furan, imidazole, thiophene, thiazole, or derived from benzene, pyridine, a diazine, pyrimidine, substituted or not at the terminal amino group with an acylic group, or containing, in place of the free or substituted amino group a carboxamido group, and R_3 or R_4 are equal or different lower alkyl groups C_1 to C_4 .


FIELD OF INVENTION

In the therapy of many human and animal diseases the need of further improvements in the available remedies is highly desirable in view of obtaining new medical treatments endowed with higher efficacy in the absence of unwanted side effects. This is particularly urgent in the case of viral and cancer diseases and in different parasitic diseases, among which malaria is of the greatest importance because of the high number of victims it causes in underdeveloped countries (and not only in these), as well as in the case of many bacterial infections because of the development of resistance phenomena and of the reduced immune defence mechanisms in patients with AIDS or undergoing anticancer chemotherapy.


The availability of active principle endowed with potential efficacy is however not always sufficient without the solution of therapeutic problems related with their stability, bio-availability and/or tissue distribution. Therefore the need arises of appropriate, albeit not yet available, active formulations. This is the case with the lexitropsins, a class of chemical substances displaying potentially useful activity in severe health conditions due to viral infections, tumour development, protozoarian and bacterial infections.

In the following text we disclose an original solution of the problem related with the bio-availability of these substances that, according to our invention, are employed in the form of phospholipid complexes, preferably constituted by a liposomal system. Liposomes are discrete particles formed spontaneously when amphiphatic lipids are dispersed in excess water (Liposome Methodology, vol. 107, Leserman & Barbet Eds. INSERM Publications, Paris, 1982). The lipid molecules arrange themselves by exposing their polar head groups towards the aqueous phase while the hydrophobic hydrocarbon moieties stick together thus giving rise to bilayers which eventually take the form of multiple concentric spheres retaining an internal aqueous phase separated from the rest of the solution (multilamellar liposomes).


Lexitropsins are defined as compounds characterized by the presence of the residue of 1-methyl-4-aminopyrrole-2-carboxylic acid as the monomeric unit in a linear peptide type structure generally displaying a basic group such as an amidine or a substituted amine or guanidine at the C-terminal position, and a variety of acyl moieties or a carboxamide group at the N-terminal position. The lexitropsins may be microbial products or synthetic analogues of the same. In this latter case, in the place of a residue of 1-methyl-4-aminopyrrole-2-carboxylic acid one may find a similar derivative containing however a different heterocyclic or aromatic ring. Some example of known lexitropsin structures are presented in the following (formulas II-VIII a-i). Lexitropsins are endowed with interesting and useful pharmacological properties: within the group of known compounds we find exhibition of antiviral, antitumour, antiprotozoarian and antibacterial activities.




II



III












IV (n=0); V (n=2); VI (n=3); VII (n=4)



VIII a-i

Values of R:



PREVIOUS ART

5 Scientific literature on lexitropsins is today quite wide, but no publication or patent specifically claiming or describing liposomal or micellar

formulations or, more generally, formulations based on the formation of phospholipidic complexes of lexitropsins have appeared to date.

As for the active principles exemplified here, they have been object of preceding inventions: Distamycin and distacin, F. Arcamone et al., *Ger. Offen.* 1039198 (Sept. 18, 1957), *CA* 55, 2012f. Pyrroles, F. Arcamone et al. *Belg. Pat.* 666612 (Nov. 3, 1965), *CA* 65, 5444d Preparation of distamycin derivatives as antiviral, antitumor agents, F. Animati et al. *PCT Int. Appl. WO* 92 9,574 (Jun 11, 1992), *CA* 117, 130993. Preparation of distamycin analogs as antiviral and antitumor agents, F. Animati et al. *PCT Int. Appl. WO* 92 14,707 (Sep 3, 1992), *CA* 118, 38687; Preparation of Distamycin A derivatives as antimalarials. F. Animati et al., *PCT Int. Appl. WO* 94 25,436 (Nov. 10, 1994), *CA* 122, 105530.


The same compounds exemplified here are reported in scientific publications: Distamycin A. I. Isolation and structure of the antiviral agent distamycin A, F. Arcamone et al. *Gazz. Chim. Ital.*, **97**, 1097-1109 (1967); Distamycin A. II. Total synthesis, S. Penco et al., *ibid.*, **97**, 1110-1115 (1967). Distamycin A. III. Synthesis of analogs with modifications in the side chains, F. Arcamone et al., *Gazz. Chim. Ital.*, **99**, 620-631 (1969). Distamycin A. IV. Synthesis of analogs with different numbers of 1-methyl-4-aminopyrrole-2-carboxylic acid residues, F. Arcamone et al., *Gazz. Chim. Ital.*, **99**, 632-640 (1969). Synthesis, DNA binding and antiviral activity of distamycin analogs containing different heterocyclic moieties, F. Arcamone et al. *Anticancer Drug Design*, **1**, 235-44 (1986). Biological activity and DNA sequence specificity of synthetic carbamoyl analogues of distamycin. A. Alfieri et al., *Antiviral Chemistry and Chemotherapy*, **8**, 243-254 (1997).

DESCRIPTION OF THE INVENTION

The present invention is related to pharmaceutical formulations constituted by a phospholipidic phase containing a lexitropsin and their use



for the medical treatment of local and general infections as well as of tumour diseases in humans and in animals. Such formulations exhibit optimal pharmacological properties in respect to other formulations when used for the topical and parenteral administration of antiinfective or antitumour agents
5 belonging to the class of the lexitropsins.

Typical objects of the present invention are liposomal or micellar preparations or phospholipidic complexes of distamycin (also known as stallimycin, formula II), netropsin (formula III) an analogue thereof (formulas IV-VIII a-i), or other compounds, such as IX, X and any analogue included in
10 the general structure I useful for the preparation of medical prescriptions against infectious or cancer diseases in humans and in animals.



IX

According to the present invention the pharmacological activity of every bioactive lexitropsin, being lexitropsin a chemical compound as defined above, is markedly improved by the phospholipidic formulation disclosed here
15 and the latter can be employed in the medical treatment of local and general infections due to responsive pathogens and of cancer. An additional series of lexitropsin derivatives utilized within the scope of the present invention are the bis-amidine analogues of general structure XI (n=1-4) that are endowed with interesting antiviral and antibacterial activity and whose therapeutic
20 efficacy could also be greatly improved by the use of the liposomal formulations described in the present invention.



A typical embodiment of the present invention is the preparation of multilamellar liposomes, composed of phosphatidyl glycerol (PG), phosphatidyl choline (PC) and cholesterol (C) containing an entrapped
 5 lexitropsin in an amount comprised in the range 1-10 percent of the mass of the liposome. Another typical embodiment of the present invention is the preparation of phospholipidic vesicles composed by polyethylene glycol ethanolamine (PEGPE), PG and partially hydrogenated egg phosphatidyl choline (PHEPC) containing 1-10% by weight of a lexitropsin. A further
 10 typical embodiment of the present invention is the preparation of liposomes and phospholipidic complexes containing a lexitropsin in sterile and apyrogenic form. A preferred object of the present invention are liposomal formulations as described above entrapping specifically a lexitropsin of general formula I.

15 An important embodiment of the present invention is represented by the topical use in localized viral or tumour diseases of liposomal or micellar preparations or of phospholipidic complexes of distamycin II, or of an analogue thereof such as for instance a compound of structures III, IV, V, VI, VII, VIII, IX, X, XI, in the understanding that the invention is not limited to
 20 the use of the specific compounds indicated herein. A further important embodiment of the present invention is also the therapeutic use of sterile and

apyrogenic liposomal or micellar preparation, or of phospholipidic complexes containing a lexitropsin of general formula I for the treatment by a parenteral route of local or generalized infections as well as of cancer in humans and in animals. Such formulations allow the exhibition of optimal pharmacological properties of anti-infective or anti-tumour agents belonging to the chemical class of the lexitropsins. In consequence a preferred embodiment is the parenteral use of liposomes entrapping a compound of general formula I, as for example compounds II -XI, for the treatment of viral diseases. Compound X is known as endowed of marked antimalarial activity. This property is significantly enhanced when the compound is used in the formulation as described above and can therefore be employed for the treatment of malaria in man.

A further object of the present invention is represented by the use of the above mentioned formulations for the production of pharmaceutical preparations containing them.

EXAMPLES

Example 1

Multilamellar liposomes are prepared by dissolving 60 micromoles of the mixture PG:PC:cholesterol (in chloroform) in the molar ratios 1:4:4 and 3 micromoles of a lexitropsin of general formula I, as an organic or inorganic acid salt (preferably the hydrochloride) in methanol, the mixture being then evaporated at room temperature in a rotary evaporator under vacuum. To the residue is then added at 37° physiological solution buffered at pH 7.4 with Tris.HCl (10 ml) and the resulting suspension is stirred at 37° overnight. The obtained heterogeneous suspension of multilamellar liposomes is extruded through a porous filter (0.2-0.4 micron) under nitrogen at a pressure of 40-80 psi at room temperature, then centrifuged at 130000 x g for one hour in order to remove the non-entrapped lexitropsin. Liposomes so obtained are taken up

as a suspension in 1 ml of physiological solution, dialyzed against 100 volumes of physiological solution at 37°C and the resulting suspension is freeze-dried in a glass vial. The final product contains more than 65% of the starting lexitropsin.

5 Example 2

A chloroform solution containing 50 mg each of phosphatidyl glycerol (PG), phosphatidyl choline (PC), cholesterol (C), is evaporated in a rotary evaporator at reduced pressure and all traces of solvent are removed with a current of nitrogen. The resulting lipid film is hydrated with 3 ml of
10 physiological solution containing 39 micromoles of a lexitropsin of formula I as the salt of an organic or inorganic acid (preferably the hydrochloride) under stirring with a vibromixer apparatus at 30 sec. intervals and with standing in a water bath at 60°C for the same period of time for a total time of 10 min. The obtained liposomal suspension is sonicated under nitrogen for 2 min. in a
15 sanitation bath, then cooled in a bath of ice an water for 1 min. Liposomes so obtained are recovered by ultracentrifugation at 130,000 x g for 20 min., then resuspended in water containing 10% (w/w) lactose and freeze-dried. The yield of entrapped lexitropsin is 90%.

Example 3

20 Multilamellar liposomes containing entrapped a lexitropsin of general formula I, obtained as described in examples 1 and 2 are recovered, instead of using a centrifugation step, by ultrafiltration at cut-off comprised in the range 1000-5000 daltons, taken up in 10% (w/w) aqueous lactose and freeze-dried.

Example 4

25 Multilamellar liposomes containing entrapped a lexitropsin of general formula I, obtained as described in example 1 or 2, are dialyzed against 100-200 ml of physiological solution at 37° then sterilized by filtration and the filtrate is distributed in sterile and pyrogen-free conditions in sterile vials and

lyophilised.

Example 5

Multilamellar liposomes containing entrapped lexitropsin of general formula I, obtained as described in example 3, are taken up in 10% aqueous lactose and sterilized by filtration. The sterile solution of the liposomes is finally distributed in sterile ant pyrogen-free conditions in sterile vials and lyophilised.

Example 6

Vesicle forming lipids PEG-PE (polyethylen glycol phosphatidyl ethanolamine), PG, PHEPC (partially hydrogenated egg phosphatidyl choline) and cholesterol in the molar ratio 0.15:0.3:1.85:1 are dissolved in chloroform at a final total lipid concentration of 25 micromoles of phospholipid/ml. The solvent is removed under reduced pressure and the resulting dry lipid film is hydrated with a warm (60°C) solution of 10mM of a lexitropsin of general formula I as the salt of an organic or inorganic acid (preferably as the hydrochloride) in 0.9% aqueous NaCl. The hydration is performed using 1 ml of the aqueous solution for 50 micromoles of phospholipid with with 10 cycles of freezing and thawing using liquid nitrogen and a warm water bath. Optimal size of the liposomes is obtained by extrusion through two polycarbonate membranes, three cycles using 0.4 micron filters and three cycles using 0.2 micron filters. Final dimension of the liposomes is of the order of 0.1 micron in diameter. The liposomes so obtained are dialyzed against 50-100 volumes of a 5% aqueous lactose solution three times for a total time of 24 h. A fourth dialysis step lasting one h is finally performed against a solution of 5% lactose at pH comprised in the range 6.5 – 7. The non-entrapped fraction of lexitropsin is removed by treatment with a mixed bed of acid and basic ion-exchange resins followed by 5 min. low speed centrifugation. The liposomal suspension is then sterilized through filtration through a 0.45 micron

membrane, lyophilised and stored at 5°C.

Example 7

Multilamellar liposomes are prepared by dissolving 60 micromoles of the mixture PG:PC:cholesterol (in chloroform) in the molar ratios 1:4:4 and
5 1.5 mg of distamycin (II) as the hydrochloride in methanol. The mixture is evaporated in a round bottomed flask under reduced pressure and at room temperature. The resulting residue is taken up at 37°C with a physiological solution buffered at pH 7.4 with tris-hydroxymethylaminomethane.HCl buffer and stirred at 37°C overnight. The heterogeneous liposomal suspension is
10 extruded through a 0.2-0.4 micron porous filter under nitrogen at a pressure of 40-80 psi at room temperature then ultracentrifuged at 130000 x g for one h at room temperature in order to remove non-entrapped II. The liposomes so obtained are dialyzed against 100-200 volumes of physiological solution and lyophilised. The yield of entrapped distamycin is higher then 65% of the
15 amount of the starting sample.

Example 8

A chloroform solution containing 50 mg each of phosphatidyl glycerol (PG), phosphatidyl choline (PC), cholesterol (C), is evaporated in a rotary evaporator at reduced pressure and all traces of solvent are removed with a
20 current of nitrogen. The resulting lipid film is hydrated with 3 ml of physiological solution containing 15 mg of distamycin (II) hydrochloride under stirring with a vibromixer apparatus for 30 sec. followed by standing in a water bath at 60°C for the same period of time in repeated cycles for a total time of 10 min. The obtained liposomal suspension is sonicated under nitrogen
25 for 2 min. in a sonication bath, then cooled in a bath of ice an water for 1 min. Liposomes so obtained are recovered by ultracentrifugation at 130,000 x g for 20 min., then resuspended in water containing 10% (w/w) lactose and freeze-dried. The yield of entrapped distamycin is 90%.

Example 9

Multilamellar liposomes, obtained as described in examples 7 or 8, after extrusion through the porous filter, are freed from non-entrapped distamycin and recovered by an ultrafiltration step at cut-off comprised in the range 1000-
5 5000 Dalton instead of the ultracentrifugation step, then taken up in physiological solution and lyophilized.

Example 10

Multilamellar liposomes are prepared by dissolving 60 micromoles of the mixture PG:PC:cholesterol (in chloroform) in the molar ratios 1:4:4 and
10 1.5 mg of compound X as the hydrochloride in methanol. The mixture is evaporated in a round bottomed flask under reduced pressure and at room temperature. The resulting residue is taken up at 37°C with a physiological solution buffered at pH 7.4 with tris-hydroxymethylaminomethane.HCl buffer and stirred at 37°C overnight. The heterogeneous liposomal suspension is
15 extruded through a 0.2-0.4 micron porous filter under nitrogen at a pressure of 40-80 psi at room temperature then ultracentrifuged at 130000 x g for one h at room temperature in order to remove non-entrapped X in the supernatant and recover the liposomal preparation in the centrifugation pellet.. The liposomes so obtained are resuspended and dialyzed against 100-200 volumes of
20 physiological solution, then distributed in sterile and pyrogen-free conditions in sterile glass vials and lyophilised. The yield of entrapped distamycin is higher then 65% of the amount of the starting sample.

Example 11

A chloroform solution containing 50 mg each of phosphatidyl glycerol
25 (PG), phosphatidyl choline (PC), cholesterol (C), is evaporated in a rotary evaporator at reduced pressure and all traces of solvent are removed with a current of nitrogen. The resulting lipid film is hydrated with 3 ml of physiological solution containing 30 micromoles of compound X under

stirring with a vibromixer apparatus for 30 sec. followed by standing in a water bath at 60°C for the same period of time in repeated cycles for a total time of 10 min. The obtained liposomal suspension is sonicated under nitrogen for 2 min. in a sonication bath, then cooled in a bath of ice an water for 1 min.

- 5 Liposomes so obtained are recovered by ultracentrifugation at 130,000 x g for 20 min., then resuspended in water containing 10% (w/w) lactose and filtered through a standard sterilization filter, distributed in sterile and pyrogen-free conditions in sterile glass vials and then freeze-dried. The yield of entrapped X is 90%.

10 Example 12

Multilamellar liposomes, obtained as described in examples 10 or 11, after extrusion through the porous filter, are freed from non-entrapped X and recovered by an ultrafiltration step at cut-off comprised in the range 1000-50000 Dalton instead of the ultracentrifugation step, than taken up in
15 physiological solution and lyophilised in sterile and pyrogen free conditions in sterile glass vials.

Example 13

Vesicle forming lipids PEG-PE, PG, PHEPC and cholesterol in the molar ratio 0.15:0.3:1.85:1 are dissolved in chloroform at a final total lipid
20 concentration of 25 micromoles of phospholipid/ml. The solvent is removed under reduced pressure and the resulting dry lipid film is hydrated with a warm (60°C) solution of 10mM of compound X as the hydrochloride in 0.9% aqueous NaCl. The hydration is performed using 1 ml of the aqueous solution for 50 micromoles of phospholipid with 10 cycles of freezing and thawing
25 using liquid nitrogen and a warm water bath. Optimal size of the liposomes is obtained by repeated extrusion through two polycarbonate membranes, three cycles using 0.4 micron filters and three cycles using 0.2 micron filters. Final dimension of the liposomes is of the order of 0.1 micron in diameter. The

liposomes so obtained are dialyzed against 50-100 volumes of a 5% aqueous lactose solution three times for a total time of 24 h. A fourth dialysis step lasting one h is finally performed against a solution of 5% lactose at pH comprised in the range 6.5 to 7. The non-entrapped fraction of lexitropsin X is removed by treatment with a mixed bed of acid and basic ion-exchange resins followed by 5 min. low speed centrifugation. The liposomal suspension is then sterilized through filtration through a 0.22 micron membrane, lyophilised and stored at 5°C.

Example 14

Multilamellar liposomes are prepared as described in example 10 above substituting compound X with compound XI. The yield of entrapment is higher than 65%.

Example 15

Multilamellar liposomes are prepared as described in example 11 above substituting compound X with compound XI. The yield of entrapment is 90%.

Example 16

Multilamellar liposomes are prepared as described in example 12 above substituting compound X with compound XI.

Example 17

Multilamellar liposomes are prepared as described in example 13 above substituting compound X with compound XI

Example 18

A lexitropsin preparation, obtained as described in examples 1 to 17 is administered in a topical formulation onto the affected skin of the patient in such amount as to apply 5-50 mg of the active principle in each single application two-three times a day for a period of 5 to 7 consecutive days.


Example 19

A lexitropsin preparation, obtained as described in examples 4 to 6 and

10 to 17 is administered by parenteral route, that is by intravenous, intramuscular or subcutaneous injection, to patients affected by a disease respondent to the lexitropsin medication at a dosage comprised in the range of 5 to 500 mg once a day for a period of 2 to 7 consecutive days.

CLAIMS

1. A phospholipidic preparation consisting in a release system and a lexitropsin of general formula I



I (n=0,1)

in which R_1 is a functional group, preferably a basic one such as a simple or substituted amidine, a secondary or tertiary amine, a quaternary ammonium group, a simple or substituted guanidine, examples of which, without limiting the present invention, may be


-C(NH)NH₂, -C(NH)NHR₃, -NH₂, NHR₃, -N(R₃)₂, -NR₃R₄,
-NH-C(NH)NH₂, -NH-C(NH)NHR₃, -N(CH₂)₄, -N(R₃)₃⁺

whereas R_2 represents an aliphatic, aromatic, or arylaliphatic acyclic group, also if substituted with atomic groups containing one or more heteroatoms such as atoms of oxygen, nitrogen, or R_2 represents a sequence of one or more residues of 1-methyl-4-aminopyrrole-2-carboxylic acid, acylated or not acylated at the N-terminus, also terminating with a residue of 1-methyl-4-carboxamidopyrrole-2-carboxylic acid or with a residue of analogue amino acids derived from a heterocycle different from pyrrole such as, without limiting the present invention, furan, imidazole, thiophene, thiazole, or derived from benzene, pyridine, a diazine, pyrimidine, substituted or not at the terminal amino group with an acyclic group, or containing, in place of the free or substituted amino group a carboxamido group, and R_3 or R_4 are equal or

different lower alkyl groups C₁ to C₄,

the release system being a liposome, a micelle, a nanoparticle, a phospholipidic complex or in general terms a supramolecular phospholipidic structure able to incorporate a compound of general structure I in stable and reversible form.


2. A phospholipidic preparation, consisting in a release system and of distamycin (II) in the form of an organic or inorganic salt, preferably as the hydrochloride,



II

in which the release system is a liposome, a micelle, a nanoparticle, a phospholipidic complex or in general terms a supramolecular phospholipidic structure able to incorporate II in stable and reversible form.

3. A phospholipidic preparation, consisting of a release system and of compound X in the form of an organic or inorganic salt, preferably as the hydrochloride,



X

in which the release system is a liposome, a micelle, a nanoparticle, a

phospholipidic complex or in general terms a supramolecular phospholipidic structure able to incorporate X in stable and reversible form.

4. A topical formulation based on a lexitropsin preparation as in claim 1, containing from 0.1 to 10% of active principle of general formula I, for the treatment of local microbial, viral or protozoan infections and for the treatment of localized tumours.

5. An injectable formulation, based on a lexitropsin preparation as in claim 1, for the medical treatment by a parenteral route, preferably by the intravenous, intramuscular, subcutaneous route, of generalized microbial, viral, protozoan infections or of disseminated tumours, at dosages comprised from 0.1 to 20 mg of a lexitropsin of general formula I per kg body weight.

6. A topical formulation based on a lexitropsin preparation as in claim 2 containing from 0.1 to 10% of active principle of general formula II, for the treatment of local microbial, viral or protozoan infections and for the treatment of localized tumours.

7. An injectable formulation, based on a lexitropsin preparation as in claim 2, for the medical treatment by a parenteral route, preferably by the intravenous, intramuscular or subcutaneous route, of generalized microbial, viral, protozoan infections or of disseminated tumours, at dosages comprised from 0.1 to 20 mg of a lexitropsin of general formula II per kg body weight.

8. A topical formulation based on a lexitropsin preparation as in claim 3 containing from 0.1 to 10% of active principle of general formula X, for the treatment of local microbial, viral or protozoan infections and for the treatment of localized tumours.

9. An injectable formulation, based on a lexitropsin preparation as in claim 3, for the medical treatment by a parenteral route, preferably by the intravenous, intramuscular or subcutaneous route, of generalized microbial, viral, protozoarian infections or of disseminated tumours, at dosages

comprised from 0.1 to 20 mg of a lexitropsin of general formula X per kg body weight.

INTERNATIONAL SEARCH REPORT

International Application No

P 03/06745

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/127 A61K31/155 A61K31/167 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 35935 A (ONCOZYME PHARMA INC.) 25 May 2001 (2001-05-25) page 8, line 13,14 page 9, line 1-3,18-24 page 28, line 15,24-26 ----	1,2,4-7
A	US 6 187 572 B1 (GOODRICH JR RAYMOND P ET AL) 13 February 2001 (2001-02-13) column 16, line 34-37 column 27, line 53-56 ----	1-9
A	US 2002/037856 A1 (KHORLIN ALEXANDER ET AL) 28 March 2002 (2002-03-28) paragraph '0008! - paragraph '0018! paragraph '0157! ----- -/--	1-9

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

13 November 2003

Date of mailing of the international search report

25/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Vermeulen, S

INTERNATIONAL SEARCH REPORT

International Application No

PO 03/06745

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 766 142 A (ARCAMONE FEDERICO ET AL) 23 August 1988 (1988-08-23) column 1, line 1 -column 2, line 7 column 14, line 33-49 -----	1-9

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/06745

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0135935	A	25-05-2001	AU 1376501 A	30-05-2001
			WO 0135935 A2	25-05-2001
			CA 2388674 A1	25-05-2001
			EP 1231910 A2	21-08-2002
			JP 2003515534 T	07-05-2003
US 6187572	B1	13-02-2001	US 5418130 A	23-05-1995
			US 6169109 B1	02-01-2001
			US 5587490 A	24-12-1996
			US 5516629 A	14-05-1996
			US 6251644 B1	26-06-2001
			US 5789601 A	04-08-1998
			US 5869701 A	09-02-1999
			US 5798238 A	25-08-1998
			US 5955256 A	21-09-1999
			AT 203679 T	15-08-2001
			AU 3476593 A	01-09-1993
			CA 2128866 A1	05-08-1993
			DE 69330514 D1	06-09-2001
			DE 69330514 T2	28-03-2002
			EP 0633786 A1	18-01-1995
			JP 2001509773 T	24-07-2001
			NO 942781 A	15-09-1994
			WO 9314791 A2	05-08-1993
			ZA 9300587 A	07-07-1994
			AT 232737 T	15-03-2003
			AU 653337 B2	29-09-1994
			AU 7693591 A	11-11-1991
			DE 69133198 D1	27-03-2003
			DE 69133198 T2	24-07-2003
			EP 0483304 A1	06-05-1992
			JP 3373201 B2	04-02-2003
			WO 9116060 A1	31-10-1991
			CA 2056619 A1	17-10-1991
			JP 5500971 T	25-02-1993
			US 5342752 A	30-08-1994
			ZA 9102842 A	25-03-1992
US 2002037856	A1	28-03-2002	US 2003119749 A1	26-06-2003
			AU 7018301 A	08-01-2002
			BR 0112030 A	29-04-2003
			CA 2414512 A1	03-01-2002
			CN 1439006 T	27-08-2003
			EP 1294713 A2	26-03-2003
			NO 20025720 A	26-02-2003
			WO 0200650 A2	03-01-2002
US 4766142	A	23-08-1988	AT 387013 B	25-11-1988
			AT 188886 A	15-04-1988
			AU 587841 B2	31-08-1989
			AU 6020286 A	22-01-1987
			BE 905110 A1	15-01-1987
			CA 1285934 C	09-07-1991
			CH 674206 A5	15-05-1990
			CN 86104787 A , B	18-02-1987
			CS 8904883 A2	12-03-1991
			CS 8605412 A2	12-03-1991
			DE 3623880 A1	29-01-1987

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC 03/06745

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4766142	A	DK 335986 A	17-01-1987
		ES 2000502 A6	01-03-1988
		FI 862959 A ,B,	17-01-1987
		FR 2585018 A1	23-01-1987
		GB 2178036 A ,B	04-02-1987
		GR 861841 A1	18-11-1986
		HU 43088 A2	28-09-1987
		IE 59073 B1	12-01-1994
		IL 79402 A	10-06-1991
		IT 1196488 B	16-11-1988
		JP 2047861 C	25-04-1996
		JP 7080843 B	30-08-1995
		JP 62077362 A	09-04-1987
		KR 9310496 B1	25-10-1993
		NL 8601837 A	16-02-1987
		NO 862860 A ,B,	19-01-1987
		NZ 216829 A	29-03-1989
		PH 24714 A	01-10-1990
		PT 82984 A ,B	01-08-1986
		SE 468642 B	22-02-1993
		SE 8603098 A	17-01-1987
		SU 1544185 A3	15-02-1990
		SU 1609445 A3	23-11-1990
		ZA 8605263 A	25-03-1987